Sanofi Pursues Genzyme, But For How Long?
Sanofi-Aventis SA's hostile bid for Genzyme Corp. creates difficult choices for the Cambridge, Mass.-based biotech's investors. Do they continue to trust Genzyme's management team, despite its track record of missteps and overly enthusiastic and frequently wrong guidance? Or should they cash out now while there is a clear and certain opportunity?
You may also be interested in...
Experts say robust quality systems, if taken to heart, can play a key role in preventing and recovering from manufacturing failures like the ones that have struck Genzyme and Johnson & Johnson in recent months.
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.